Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
Yang YS, Min KW, Park SO, Kim KS, Yu JM, Hong EG, Cho SR, Won KC, Kim YH, Oh S, Choi SH, Koh G, Huh W, Kim SY, Park KS. Yang YS, et al. Among authors: yu jm. Diabetes Obes Metab. 2023 Aug;25(8):2096-2104. doi: 10.1111/dom.15080. Epub 2023 Apr 24. Diabetes Obes Metab. 2023. PMID: 37016484 Clinical Trial.
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension.
Moon JS, Park IR, Kim HJ, Chung CH, Won KC, Han KA, Park CY, Won JC, Kim DJ, Koh GP, Kim ES, Yu JM, Hong EG, Lee CB, Yoon KH. Moon JS, et al. Among authors: yu jm. Diabetes Metab J. 2023 Nov;47(6):808-817. doi: 10.4093/dmj.2022.0387. Epub 2023 Sep 26. Diabetes Metab J. 2023. PMID: 37750183 Free PMC article. Clinical Trial.
Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double-blind, randomized controlled trial.
Lee YH, Kim DM, Yu JM, Choi KM, Kim SG, Park KS, Son HS, Chung CH, Ahn KJ, Lee SH, Song KH, Kwon SK, Park HK, Won KC, Jang HC; ACACIA Study Group. Lee YH, et al. Among authors: yu jm. Diabetes Obes Metab. 2023 May;25(5):1174-1185. doi: 10.1111/dom.14959. Epub 2023 Jan 10. Diabetes Obes Metab. 2023. PMID: 36564983 Clinical Trial.
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.
Kwak SH, Han KA, Kim KS, Yu JM, Kim E, Won JC, Kang JG, Chung CH, Oh S, Choi SH, Won KC, Kim SG, Cho SA, Cho BY, Park KS. Kwak SH, et al. Among authors: yu jm. Diabetes Obes Metab. 2023 Jul;25(7):1865-1873. doi: 10.1111/dom.15046. Epub 2023 Mar 23. Diabetes Obes Metab. 2023. PMID: 36872067 Clinical Trial.
809 results